Abnormal myocardial enzymes in the prediction of mortality and hypertension in COVID-19 patients: a retrospective study

Sha, Shuang; Liu, Min; Sun, Menghong; Xiao, Long; Chang, Qing; Chen, Ying; Huang, Jie

doi:10.18632/aging.204362

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But there were some studies reporting con icting results as well. A study found CK-MB and CK had no signi cant difference in the prediction effect of the mortality in COVID-19 (41). The disagreement of CK and CK-MB found in our study made it di cult to clarify whether patients in the control group had more severe cardiac damage than patients in the baricitinib group.…”

Section: Discussioncontrasting

confidence: 76%

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation：a propensity score-matched and retrospective analysis

Mao

Guo

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Baricitinib is a selective inhibitor of Janus kinase (JAK)1 and JAK2, which is associated with clinical improvement in non-severe COVID-19 patients. But in severe COVID-19 patients, the efficacy of baricitinib is still controversial. Methods: A propensity score-matched and retrospective study was conducted to evaluate the efficacy of baricitinib in severe COVID-19 patients requiring invasive mechanical ventilation (IMV). Results: A total number of 46 patients treated with baricitinib were included, and 44 patients were assigned to control group by propensity score matching. The mean ages were high in both group (baricitinib group vs control group: 78.80±9.04 vs 82.57±9.27), and most were unvaccinated (65.2% vs 72.7%). Baricitinib group had a higher proportion of patients with hypertension (73.9% vs 45.5%). Control group had higher level of creatine kinase-myocardial band (247.50 vs 104.50). Patients in the baricitinib group were more likely to receive nirmatrelvir/ritonavir (41.3% vs 18.2%) and intravenous immunoglobin (15.2% vs 0). Both groups reported high all-cause 28-day mortality (73.9% vs 84.1%). The use of baricitinib didn’t reduce 28-days mortality. Conclusion: The present study revealed baricitinib didn’t reduce 28-days mortality in severe COVID-19 patients on IMV. The effectiveness of baricitinib in treating patients with severe COVID-19 on IMV needs to be further investigated through future studies.

show abstract

Section: Discussioncontrasting

confidence: 76%

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation：a propensity score-matched and retrospective analysis

Mao

Guo

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…They further suggested that hs-TnI and CK-MB levels could serve as important biomarkers for identifying COVID-19 patients with cardiac damage [44]. Sha et al found that the levels of CK and CK-MB were significantly higher in patients with severe COVID-19 disease compared to those with non-severe disease, and the levels of CK and CK-MB correlated positively with the severity of the disease [45]. The study by Shi et al found that patients with cardiac injury had higher levels of troponin I, myoglobin, and CK-MB than those without cardiac injury.…”

Section: Creatine Kinase-myocardial Bandmentioning

confidence: 99%

Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients

Yaluri,

Stančáková Yaluri,

Žeňuch

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a global health concern, causing significant morbidity and mortality. Both lifestyle and genetics influence the development of CVD. It is often diagnosed late, when the treatment options are limited. Early diagnosis of CVD with help of biomarkers is necessary to prevent adverse outcomes. SARS-CoV-2 infection can cause cardiovascular complications even in patients with no prior history of CVD. This review highlights cardiovascular biomarkers, including novel ones, and their applications as diagnostic and prognostic markers of cardiovascular complications related to SARS-CoV-2 infection. Patients with severe SARS-CoV-2 infection were shown to have elevated levels of cardiac biomarkers, namely N-terminal pro-brain natriuretic peptide (NT-pro-BNP), creatine kinase-myocardial band (CK-MB), and troponins, indicating acute myocardial damage. These biomarkers were also associated with higher mortality rates and therefore should be used throughout COVID-19 patient care to identify high-risk patients promptly to optimize their outcomes. Additionally, microRNAs (miRNAs) are also considered as potential biomarkers and predictors of cardiac and vascular damage in SARS-CoV-2 infection. Identifying molecular pathways contributing to cardiovascular manifestations in COVID-19 is essential for development of early biomarkers, identification of new therapeutic targets, and better prediction and management of cardiovascular outcomes.

show abstract

Associations between antibiotic exposure and abnormal cardiac enzyme profiles in older Chinese adults

Zheng,

Ni,

Wang

et al. 2023

Environ Sci Pollut Res

View full text Add to dashboard Cite

Abnormal myocardial enzymes in the prediction of mortality and hypertension in COVID-19 patients: a retrospective study

Cited by 3 publications

References 35 publications

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation：a propensity score-matched and retrospective analysis

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation：a propensity score-matched and retrospective analysis

Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients

Associations between antibiotic exposure and abnormal cardiac enzyme profiles in older Chinese adults

Contact Info

Product

Resources

About